AUTHORS
Kai Wan, Wen Qin, MD2, Xue Liu3, Xiao Han4, Hongju Yan5, Zhang Mengyun6, Dongfeng Zeng, PhD7, Li Wang8, Qianwei Lu9, Cheng Zhang, MD10, Xi Zhang, MD11
AFFILIATIONS
1 Xinqiao Hospital Army Medical University, Chongqing, China
2 Xinqiao Hospital Army Medical University, Chongqing, China
3 Xinqiao Hospital Army Medical University, Chongqing, China
4 Xinqiao Hospital Army Medical University, Chongqing, China
5 Xinqiao Hospital Army Medical University, Chongqing, China
6 Xinqiao Hospital Army Medical University, Chongqing, China
7 Army Medical University Army Characteristic Medical Center (Daping Hospital), Chongqing, China
8 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
9 The Ninth People's Hospital of Chongqing, Chongqing, China
10 Xinqiao Hospital Army Medical University, Chongqing, China
11 Xinqiao Hospital Army Medical University, Chongqing, China
ABSTRACT
Background: Relapsed or refractory acute myeloid leukemia (R/R AML) carries a poor prognosis with currently no standard salvage therapy. Intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HSCT) represents the most common treatment approach. The CLAG regimen [cladribine, cytarabine, and granulocyte colony-stimulating factor (G-CSF)] with or without mitoxantrone is a commonly used salvage regimen. Mitoxantrone hydrochloride liposome (Lipo-MIT), the first approved nano-formulation of mitoxantrone, has demonstrated improved pharmacokinetics and shown anti-leukemic activity in early-phase AML studies. We previously reported preliminary findings of Lipo-MIT combined with CLAG at ASH 2025. Here we present updated results from this trial (ChiCTR2400086291).
Methods: Eligible patients with confirmed diagnosis of R/R AML, excluding acute promyelocytic leukemia (APL), were enrolled. Patients received the Lipo-MIT (18 mg/m2, day 1) combined with CLAG (cladribine 5 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5, G-CSF 300 μg days 0-5) every 4 weeks for up to 2 cycles. The primary endpoint was the composite complete remission (CRc) rate. Secondary endpoints were overall response rate (ORR), survival, measurable residual disease (MRD) negative rate, and safety.
Results: At data cut-off on July 17, 2026, 43 patients with R/R AML were enrolled. The median age was 46 years (range, 10-64), and 55.8% were male. Among them, 24 (55.8%) had refractory disease, 19 (44.2%) had relapsed disease, and 4 (9.3%) had secondary AML. ELN 2022 risk stratification revealed 25.6% favorable, 34.9% intermediate, and 39.5% adverse. Common mutations included CEBPA (20.9%, 9/43), TP53 (7.0%, 3/43), ASXL1 (7.0% 3/43), and RUNX1 (7.0%, 3/43).
Among 43 efficacy-evaluable patients, the best CRc rate was 62.8% (27/43; 95% CI, 46.7%-77.0%), and the ORR was 69.8% (30/43; 95% CI, 53.9%-82.8%). The flow cytometric MRD negative rate among CRc patients with evaluable results was 70.6% (12/17).With a median follow-up of 4.5 months (range 0.6-35.0), the 6-month relapse-free survival (RFS) and overall survival (OS) rates were 68.8% (95% CI, 42.9-84.7) and 84.7% (95% CI, 64.0-94.0), respectively. Among the 27 CRc patients, 14 (51.9%) proceeded to HSCT (13 allogeneic). The 6-month OS rate was 92.9% (95% CI, 59.1–99.0) in the transplant group, compared with 66.7% (95% CI, 19.5-90.4) in the non-transplant group (N=13).
Hematological toxicities were the main treatment-related adverse events (TRAEs). In patients with CRc, median durations of neutropenia (<0.5×109/L) and thrombocytopenia (<25×109/L) were 28.5 days (range, 14-57) and 20 days (range, 3-57). Common grade 3/4 non-hematological TRAEs included febrile neutropenia (69.8%), infection (51.2%), and sepsis (14.0%).
Conclusions: The CLAG-M regimen continues to show promising efficacy and manageable safety in R/R AML, with encouraging post-transplant survival supporting its role as an effective bridge to allo-HSCT.
DISCLOSURES
Xiao Han: No relevant conflicts of interest to declare.